Linden Thomas Advisory Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.25M Sell
5,415
-74
-1% -$18.3K 0.1% 321
2026
Q2
$1.32M Sell
5,489
-29
-0.5% -$6.35K 0.11% 306
2026
Q1
$1.04M Buy
+5,518
New +$964K 0.1% 311

Other funds holding JAZZ

Linden Thomas Advisory Services's JAZZ Position: Q3 2026 in Review

Linden Thomas Advisory Services reduced its Jazz Pharmaceuticals (JAZZ) stake by 1.3% in Q3 2026, selling an estimated $18.3K and leaving 5,415 shares worth $1.25M. The position accounts for 0.1% of the portfolio, ranked #321.

Linden Thomas Advisory Services first reported a position in JAZZ in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.32M in Q2 2026. 671 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Linden Thomas Advisory Services held 5,415 shares of Jazz Pharmaceuticals worth $1.25M as of Q3 2026.
  • Linden Thomas Advisory Services sold 74 Jazz Pharmaceuticals shares in Q3 2026, an estimated $18.3K.
  • Jazz Pharmaceuticals made up 0.1% of Linden Thomas Advisory Services's portfolio in Q3 2026, its #321 holding.
  • Linden Thomas Advisory Services first reported a position in Jazz Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Linden Thomas Advisory Services's Jazz Pharmaceuticals position peaked at $1.32M in Q2 2026.
  • 671 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2026, filed 19 Oct 2026.